FDA approves pomalidomide to treat Kaposi's sarcoma

Recently, Bristol Myers Squibb (BMS) announced that the US FDA has accelerated the approval of Pomalyst (pomalidomide, pomalidomide) for the treatment of AIDS-related anti-retroviral therapy (HAART) -resistant Kaposi's sarcoma Patients, as well as HIV-negative Kaposi's sarcoma patients. This accelerated approval is based on the overall response rate observed in the Phase 1/2 open-label single-arm clinical trial (12-C-0047). Pomalyst has received breakthrough therapy and orphan drug certification. This oral therapy is the first new treatment option for patients with Kaposi's sarcoma in more than 20 years.

Kaposi's sarcoma (Kaposi sarcoma) is a rare cancer caused by Kaposi's sarcoma-associated herpes virus infection, which is also known as human herpes virus type 8. Patients will have multiple lesions on the skin and oral mucosal surface, and sometimes the lesions will also appear on the surface of the lung and gastrointestinal mucosa. Kaposi's sarcoma is more common among people infected with HIV. If HIV-positive patients become resistant to systemic chemotherapy or cannot tolerate systemic chemotherapy, there is no other approved treatment option, so these patients urgently need innovative treatment for this disease.